Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit ...

Devarakonda covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Scholar Rock Holding, and Incyte. According to TipRanks, Devarakonda has an average return of -2.8% and a 37.04 ...

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

Jefferies analyst Kelly Shi maintained a Buy rating on Insmed today and set a price target of $148.00. The company’s shares closed today at $122.00. Elevate Your Investing Strat ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...

Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...